Scientists have uncovered more than 1,700 new proteins that could have implications for human diseases, including cancer. Mostly very small, these proteins were found in what’s called the ‘dark proteome’, which covers gene products from previously overlooked sections of DNA. These proteins have unusual properties, motivating scientists to coin a new concept, peptideins, to help understand their potentially unique biology. Their findings are being shared with scientists worldwide in an open-source format to stimulate further research.

The new technology deploys a recently discovered CRISPR protein, Cas12a2, which acts like a paper shredder. When activated by a specific genetic target, it rips the genome apart, a lethal move that researchers can program to destroy harmful virus-infected cells or cancer cells.

How does the innate immune system distinguish pathogens from self-components while avoiding excessive immune response and inflammation? Toll-like receptors (TLRs) have provided the answer to this central question over four decades of research. This review synthesizes the multilayered and interactive regulatory mechanisms—from post-translational modifications to phase separation—that ensure balanced TLR signaling, and explores the translational promise of targeting these pathways in infectious diseases, autoimmune diseases, cancer, and inflammatory aging.